| Issue | Title | |
| Vol 2023, No 10 (2023) | Roche Pays US$7.1 B for Bowel Disease Drug from Roivant and Pfizer | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2025, No 3 (2025) | Roche Pays Zealand Pharma US$1.65 B Upfront for Obesity Drug Petrelintide | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2004, No 43 (2004) | Roche Reinvigorates Anti-Infective Franchise with Sankyo’s Antibiotic | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 31 (2002) | Roche Secured Option on Antisoma Pipeline | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 98 (2008) | Roche Seizes its Chance to Buy Genentech | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2013, No 4 (2013) | Roche Sharpens its Focus on Chinese HCV Market with Ascletis Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 11 (2013) | Roche Signals Return to Antibiotics Development with Polyphor Licensing Deal | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 41 (2003) | Roche Signs Collaborative Deals with BioFocus and ParAllele | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 42 (2003) | Roche Signs Deals with Ipsen and Aspreva | Abstract pdf |
| Business Review Editor | ||
| Vol 2024, No 7 (2024) | Roche Signs US$1.82 B Deal with Ascidian for RNA-Targeting Neurology Programmes | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2023, No 10 (2023) | Roche Signs US$2 B Partnership with Monte Rosa for Molecular Glue Medicines | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2023, No 8 (2023) | Roche Signs US$2.8 B Deal with Alnylam to Develop RNAi Therapeutic for Hypertension | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2010, No 8 (2010) | Roche Strengthens CNS Pipeline with reMYND Alliance | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 77 (2006) | Roche Subsidiary Genentech Enters into Agreement with CGI | Abstract pdf |
| Business Review Editor | ||
| Vol 2025, No 10 (2025) | Roche to Acquire 89bio and its FGF21 Analogue Lead Asset for US$3.5 B | Abstract pdf html |
| Naini Anand | ||
| Vol 2007, No 83 (2007) | Roche to Acquire BioVeris for US$21.50 per share | Abstract pdf |
| Business Review Editor | ||
| Vol 2023, No 12 (2023) | Roche to Acquire Carmot Therapeutics for US$3.1 B | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2024, No 12 (2024) | Roche to Acquire Poseida Therapeutics for US$1.5 B | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2003, No 33 (2003) | Roche to Bid US$1.2 B for Diabetes Firm, Disetronic | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 9 (2014) | Roche to Buy InterMune for US$8.3 B to Gain Pirfenidone for Idiopathic Pulmonary Fibrosis | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 67 (2006) | Roche: Recognising BioCryst's Potential? | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 31 (2002) | Roche’s Option on Antisoma | Abstract |
| Business Review Editor | ||
| Vol 2008, No 92 (2008) | Roche’s Persistence in Face of Ventana’s Opposition Pays Off | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 9 (2017) | Rocket Pharmaceuticals Reverse Merges with Inotek Pharmaceuticals to Advance Gene Therapies | Abstract pdf html |
| Natasha Piper | ||
| Vol 2008, No 92 (2008) | Royal Philips Electronics to Acquire Respironics | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 52 (2004) | Royalty Rates - What is There to Hide? | Details html |
| Fintan Walton | ||
| Vol 2007, No 89 (2007) | Royalty Rates in Pharmaceutical Licensing Deals | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 61 (2005) | Royalty Rates Used in Pharmaceutical Agreements | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 2 (2010) | Royalty Rates: Feeling Lucky | Abstract jpg |
| Taskin Ahmed | ||
| Vol 2012, No 7 (2012) | Russia’s SatRx Licenses Exclusive Rights to Pfizer’s DPP-IV Inhibitor | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 4 (2011) | RXi Pharmaceuticals Looks Beyond RNAi Therapeutics with Apthera Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 1 (2009) | S*Bio Signs Two Major Anticancer Deals | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2006, No 75 (2006) | Sales and Marketing | Details jpg |
| Business Review Editor | ||
| Vol 2013, No 11 (2013) | Salix Adds to Gastroenterology Franchise with US$2.6 B Santarus Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 11 (2011) | Salix Expands its Product Portfolio with US$300 M Oceana Therapeutics Buyout | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 82 (2007) | Salix Expands Product Portfolio through Merck & Co. Licensing Deal | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 8 (2014) | Salix Joins the Tax Inversion Wave by Agreeing to Merge with Cosmo Pharmaceuticals’ Irish Unit | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 76 (2006) | Salix Licenses Right to Market and Distribute Sanvar® from Debiopharm | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 62 (2005) | Salix to Acquire InKine in Gastrointestinal Merger | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 89 (2007) | Samples | Details jpg |
| Business Review Editor | ||
| Vol 2010, No 5 (2010) | Sandoz to acquire respiratory firm Oriel | Abstract |
| Taskin Ahmed | ||
| Vol 2018, No 1 (2018) | Sanofi Acquires Haemophilia Specialist Bioverativ for US$11.6 B | Abstract pdf html |
| Subham Nandi | ||
| Vol 2020, No 8 (2020) | Sanofi Acquires Principia for US$3.68 B | Abstract html pdf |
| Michelle Liu | ||
| Vol 2024, No 2 (2024) | Sanofi Acquires Rare Disease Developer Inhibrx for up to US$2.2 B | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2020, No 1 (2020) | Sanofi Adds Depth to its Pipeline with US$2.6 B Nurix Collaboration | Abstract html pdf |
| Subham Nandi | ||
| Vol 2017, No 5 (2017) | Sanofi and Exscientia to Develop Bispecific Molecules for Diabetes | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2009, No 11 (2009) | Sanofi and Micromet Collaborate on Early Stage Cancer Antibody | Abstract |
| Taskin Ahmed | ||
| Vol 2022, No 11 (2022) | Sanofi and miRecule Partner to Develop Novel Antibody-RNA Conjugate for Muscular Dystrophy Therapy | Abstract pdf html |
| Swati Sharan | ||
| Vol 2023, No 10 (2023) | Sanofi and Teva to Collaborate on Inflammatory Bowel Disease Treatment | Abstract pdf html |
| Lalit Mishra | ||
| Vol 2016, No 9 (2016) | Sanofi and Verily form joint venture to Personalise Diabetes Care | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2012, No 3 (2012) | Sanofi Augments its Biosurgery Unit with Pluromed Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2021, No 1 (2021) | Sanofi Bolsters Immunology Portfolio with US$1.45 B Kymab Acquisition | Abstract pdf html |
| Michelle Liu | ||
| Vol 2021, No 9 (2021) | Sanofi Bolsters Pipeline with Two Multibillion-Dollar Deals | Abstract pdf html |
| Neha Madhwani | ||
| Vol 2009, No 8 (2009) | Sanofi Boosts Vaccine Presence | Abstract |
| Taskin Ahmed | ||
| Vol 2023, No 3 (2023) | Sanofi Buys Provention Bio and its Type 1 Diabetes Drug for US$2.9 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2018, No 11 (2018) | Sanofi Collaborates with Denali for its RIPK1 Programme | Abstract pdf html |
| Michelle Liu | ||
| Vol 2012, No 9 (2012) | Sanofi Collaborates with Oncodesign to Develop Inhibitors of Challenging Kinase Targets | Abstract |
| Heather Cartwright | ||
| Vol 2022, No 10 (2022) | Sanofi Collaborates with Scribe Therapeutics in CRISPR Cell Therapy Deal | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2009, No 10 (2009) | Sanofi Continues its Buying Spree | Abstract |
| Taskin Ahmed | ||
| Vol 2018, No 6 (2018) | Sanofi Deepens Investment in mRNA Vaccines with Translate Bio Collaboration | Abstract pdf html |
| Heather Cartwright | ||
| Vol 2020, No 9 (2020) | Sanofi Delves Further into Protein Degrader Therapies with US$2.33 B Kymera Deal | Abstract pdf html |
| Ashish Tripathi & Michelle Liu | ||
| Vol 2022, No 3 (2022) | Sanofi Enters Multi-Billion Dollar Antibody Deals with Adagene and IGM | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2020, No 7 (2020) | Sanofi Expands mRNA Collaboration with Translate Bio | Abstract pdf html |
| Pratika Pahwa & Michelle Liu | ||
| Vol 2009, No 12 (2009) | Sanofi Inks Antibody Deals Targeting Infections and Alzheimer’s | Abstract |
| Taskin Ahmed | ||
| Vol 2012, No 10 (2012) | Sanofi Looks to Second-Generation Emerging Markets with Genfar Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2018, No 2 (2018) | Sanofi Makes Second Big Buy of the Month with Ablynx Acquisition | Abstract pdf html |
| Natasha Piper | ||
| Vol 2014, No 11 (2014) | Sanofi Pasteur Partners with Immune Design in Race to Develop First HSV-2 Vaccine | Abstract |
| Heather Cartwright | ||
| Vol 2024, No 9 (2024) | Sanofi Pays RadioMedix and Orano Med US$110 M Upfront for Radioligand Medicine | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2017, No 11 (2017) | Sanofi Signs Deal with Principia to Strengthen its Position in Multiple Sclerosis | Abstract pdf html |
| Natasha Piper | ||
| Vol 2015, No 12 (2015) | Sanofi Signs Trio of Deals to Bolster Diabetes and Oncology Pipelines | Abstract PDF html |
| Heather Cartwright & Rohit Khera | ||
| Vol 2022, No 11 (2022) | Sanofi Signs US$1.2 B AI Drug Discovery Deal with Insilico Medicine | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2016, No 4 (2016) | Sanofi Signs US$2.26 B Deal with Start-Up DiCE Molecules to Develop Next-Generation Oral Therapeutics | Abstract pdf html |
| Heather Cartwright & Natasha Berry | ||
| Vol 2022, No 7 (2022) | Sanofi Signs US$2.54 B Collaboration Deal with Skyhawk Therapeutics for RNA-splicing Modulators | Abstract pdf html |
| Ashish Tripathi | ||
| Vol 2025, No 6 (2025) | Sanofi to Acquire Blueprint Medicines for up to US$9.5 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2009, No 4 (2009) | Sanofi to Acquire Brazilian Generics Firm | Abstract |
| Taskin Ahmed | ||
| Vol 2025, No 3 (2025) | Sanofi to Acquire Dren Bio’s Autoimmune Bispecific Antibody for US$1.9 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2025, No 8 (2025) | Sanofi to Acquire Vicebio for up to US$1.6 B | Abstract html pdf |
| Ayush Saxena | ||
| Vol 2025, No 6 (2025) | Sanofi to Acquire Vigil Neuroscience for up to US$470 M | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2019, No 12 (2019) | Sanofi Ups Immuno-oncology Investment with US$2.5 B Synthorx Buy | Abstract pdf html |
| Michelle Liu | ||
| Vol 2017, No 7 (2017) | Sanofi Ups its Game in Vaccines Market with US$750 M Acquisition of Protein Sciences | Abstract pdf html |
| Jawala Prasad | ||
| Vol 2010, No 9 (2010) | Sanofi-aventis Acquires BMP Sunstone to Strengthen its Chinese Consumer Healthcare Position | Abstract |
| Editorial Team | ||
| Vol 2010, No 7 (2010) | Sanofi-aventis Acquires TargeGen to Strengthen its Oncology Pipeline | Abstract |
| Staff Editor | ||
| Vol 2010, No 7 (2010) | Sanofi-aventis Advances Diabetes Pipeline | Abstract |
| Staff Editor | ||
| Vol 2010, No 6 (2010) | Sanofi-Aventis and Nichi-Iko Pharmaceutical in new joint venture | Abstract |
| Debbie Tranter | ||
| Vol 2009, No 11 (2009) | Sanofi-aventis and Regeneron Extend Therapeutic Antibody Agreement | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 4 (2009) | Sanofi-aventis Circles Solvay | Abstract |
| Taskin Ahmed | ||
| Vol 2010, No 7 (2010) | Sanofi-aventis Expands its Early-Stage Pipeline | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 98 (2008) | Sanofi-Aventis Expands its Vaccine Portfolio | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2011, No 1 (2011) | Sanofi-aventis Forms Covalent Drug Discovery Partnership with Avila Therapeutics in Oncology | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 7 (2010) | Sanofi-aventis Forms microRNA Alliance with Regulus Therapeutics | Abstract |
| Staff Editor | ||
| Vol 2008, No 100 (2008) | Sanofi-aventis Gains Zentiva With Sweeter Offer | Abstract html |
| Taskin Ahmed | ||
| Vol 2009, No 12 (2009) | Sanofi-Aventis Moves into US OTC Market | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 5 (2009) | Sanofi-aventis To Acquire BiPar Sciences | Abstract |
| Taskin Ahmed | ||
| Vol 2011, No 9 (2011) | Sanofi’s Aventis Pharma Subsidiary to Acquire Nutraceuticals Business of India’s Universal Medicare | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 45 (2004) | Sanofi’s Hostile Bid for Aventis Rejected | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 4 (2013) | Santaris Pharma Gains Another Collaborator in BMS | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 2 (2014) | Santaris’ RNA-Targeting Platform Delivers Three Deals in Three Days | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 10 (2011) | Santen Pharmaceutical Strengthens its Ophthalmology Portfolio with Novagali Pharma Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 79 (2007) | Santhera Pharmaceuticals AG | Abstract |
| Business Review Editor | ||
| Vol 2006, No 68 (2006) | Satraplin | Abstract pdf |
| Business Review Editor | ||
| 2101 - 2200 of 2613 Items | << < 17 18 19 20 21 22 23 24 25 26 > >> | |